The Down Under medical sector is buzzing with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing impressive results in early trials for addressing obesity. This https://auresortwear.com/2026/06/10/retatrutide-australia-my-deep-dive-into-weight-loss-treatments/